Hepatitis C virus core protein modulates several signaling pathways involved in hepatocellular carcinoma
|
摘要
Hepatocellular carcinoma(HCC) is the fifth most common cancer, and hepatitis C virus(HCV) infection plays a major role in HCC development. The molecular mechanisms by which HCV infection leads to HCC are varied. HCV core protein is an important risk factor in HCV-associated liver pathogenesis and can modulate several signaling pathways involved in cell cycle regulation, cell growth promotion, cell proliferation, apoptosis, oxidative stress and lipid metabolism. The dysregulation of signaling pathways such as transforming growth factor β(TGF-β), vascular endothelial growth factor(VEGF), Wnt/β-catenin(WNT), cyclooxygenase-2(COX-2) and peroxisome proliferator-activated receptor α(PPARα) by HCV core protein is implicated in the development of HCC. Therefore, it has been suggested that this protein be considered a favorable target for further studies in the development of HCC. In addition, considering the axial role of these signaling pathways in HCC, they are considered druggable targets for cancer therapy. Therefore, using strategies to limit the dysregulation effects of core protein on these signaling pathways seems necessary to prevent HCV-related HCC.
Hepatocellular carcinoma(HCC) is the fifth most common cancer, and hepatitis C virus(HCV) infection plays a major role in HCC development. The molecular mechanisms by which HCV infection leads to HCC are varied. HCV core protein is an important risk factor in HCV-associated liver pathogenesis and can modulate several signaling pathways involved in cell cycle regulation, cell growth promotion, cell proliferation, apoptosis, oxidative stress and lipid metabolism. The dysregulation of signaling pathways such as transforming growth factor β(TGF-β), vascular endothelial growth factor(VEGF), Wnt/β-catenin(WNT), cyclooxygenase-2(COX-2) and peroxisome proliferator-activated receptor α(PPARα) by HCV core protein is implicated in the development of HCC. Therefore, it has been suggested that this protein be considered a favorable target for further studies in the development of HCC. In addition, considering the axial role of these signaling pathways in HCC, they are considered druggable targets for cancer therapy. Therefore, using strategies to limit the dysregulation effects of core protein on these signaling pathways seems necessary to prevent HCV-related HCC.
Hepatocellular carcinoma(HCC) is the fifth most common cancer, and hepatitis C virus(HCV) infection plays a major role in HCC development. The molecular mechanisms by which HCV infection leads to HCC are varied. HCV core protein is an important risk factor in HCV-associated liver pathogenesis and can modulate several signaling pathways involved in cell cycle regulation, cell growth promotion, cell proliferation, apoptosis, oxidative stress and lipid metabolism. The dysregulation of signaling pathways such as transforming growth factor β(TGF-β), vascular endothelial growth factor(VEGF), Wnt/β-catenin(WNT), cyclooxygenase-2(COX-2) and peroxisome proliferator-activated receptor α(PPARα) by HCV core protein is implicated in the development of HCC. Therefore, it has been suggested that this protein be considered a favorable target for further studies in the development of HCC. In addition, considering the axial role of these signaling pathways in HCC, they are considered druggable targets for cancer therapy. Therefore, using strategies to limit the dysregulation effects of core protein on these signaling pathways seems necessary to prevent HCV-related HCC.
引文
1 Fiorina L,Ricotti M,Vanoli A,Luinetti O,Dallera E,Riboni R,Paolucci S,Brugnatelli S,Paulli M,Pedrazzoli P,Baldanti F,Perfetti V.Systematic analysis of human oncogenic viruses in colon cancer revealed EBV latency in lymphoid infiltrates.Infect Agent Cancer 2014;9:18[PMID:24936208 DOI:10.1186/1750-9378-9-18]
2 White MK,Pagano JS,Khalili K.Viruses and human cancers:a long road of discovery of molecular paradigms.Clin Microbiol Rev 2014;27:463-481[PMID:24982317 DOI:10.1128/CMR.00124-13]
3 Dubuisson J,Cosset FL.Virology and cell biology of the hepatitis C virus life cycle:an update.JHepatol 2014;61:S3-S13[PMID:25443344 DOI:10.1016/j.jhep.2014.06.031]
4 Taherkhani R,Farshadpour F.Global elimination of hepatitis C virus infection:Progresses and the remaining challenges.World J Hepatol 2017;9:1239-1252[PMID:29312527 DOI:10.4254/wjh.v9.i33.1239]
5 Taherkhani R,Farshadpour F.Lurking epidemic of hepatitis C virus infection in Iran:A call to action.World J Hepatol 2017;9:1040-1042[PMID:28932350 DOI:10.4254/wjh.v9.i24.1040]
6 Maheshwari A,Ray S,Thuluvath PJ.Acute hepatitis C.Lancet 2008;372:321-332[PMID:18657711 DOI:10.1016/S0140-6736(08)61116-2]
7 Taherkhani R,Farshadpour F.Epidemiology of hepatitis C virus in Iran.World J Gastroenterol2015;21:10790-10810[PMID:26478671 DOI:10.3748/wjg.v21.i38.10790]
8 GLOBOCAN 2012 v1.0.Cancer Incidence and Mortality Worldwide:IARC CancerBase No.11.Accessed July 25;2016;Available from:http://www.globocan.iarc.fr/
9 Webster DP,Klenerman P,Dusheiko GM.Hepatitis C.Lancet 2015;385:1124-1135[PMID:25687730 DOI:10.1016/S0140-6736(14)62401-6]
10 Smith-Palmer J,Cerri K,Valentine W.Achieving sustained virologic response in hepatitis C:a systematic review of the clinical,economic and quality of life benefits.BMC Infect Dis 2015;15:19[PMID:25596623 DOI:10.1186/s12879-015-0748-8]
11 Guarino M,Sessa A,Cossiga V,Morando F,Caporaso N,Morisco F;Special Interest Group on“Hepatocellular carcinoma and new anti-HCV therapies”of the Italian Association for the Study of the Liver.Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C:A few lights and many shadows.World J Gastroenterol 2018;24:2582-2595[PMID:29962815 DOI:10.3748/wjg.v24.i24.2582]
12 Aleman S,Rahbin N,Weiland O,Davidsdottir L,Hedenstierna M,Rose N,Verbaan H,St?l P,Carlsson T,Norrgren H,Ekbom A,Granath F,Hultcrantz R.A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis.Clin Infect Dis 2013;57:230-236[PMID:23616492 DOI:10.1093/cid/cit234]
13 El-Serag HB,Kanwal F,Richardson P,Kramer J.Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.Hepatology 2016;64:130-137[PMID:26946190 DOI:10.1002/hep.28535]
14 van der Meer AJ,Feld JJ,Hofer H,Almasio PL,Calvaruso V,Fernández-Rodríguez CM,Aleman S,Ganne-CarriéN,D'Ambrosio R,Pol S,Trapero-Marugan M,Maan R,Moreno-Otero R,Mallet V,Hultcrantz R,Weiland O,Rutter K,Di Marco V,Alonso S,Bruno S,Colombo M,de Knegt RJ,Veldt BJ,Hansen BE,Janssen HLA.Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.J Hepatol 2017;66:485-493[PMID:27780714 DOI:10.1016/j.jhep.2016.10.017]
15 WHO.Hepatitis C,WHO fact sheet.Available from:http://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c
16 Smith DB,Bukh J,Kuiken C,Muerhoff AS,Rice CM,Stapleton JT,Simmonds P.Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes:updated criteria and genotype assignment web resource.Hepatology 2014;59:318-327[PMID:24115039 DOI:10.1002/hep.26744]
17 Pirakitikulr N,Kohlway A,Lindenbach BD,Pyle AM.The Coding Region of the HCV Genome Contains a Network of Regulatory RNA Structures.Mol Cell 2016;62:111-120[PMID:26924328DOI:10.1016/j.molcel.2016.01.024]
18 Tellinghuisen TL,Rice CM.Interaction between hepatitis C virus proteins and host cell factors.Curr Opin Microbiol 2002;5:419-427[PMID:12160863 DOI:10.1016/S1369-5274(02)00341-7]
19 Banerjee A,Ray RB,Ray R.Oncogenic potential of hepatitis C virus proteins.Viruses 2010;2:2108-2133[PMID:21994721 DOI:10.3390/v2092108]
20 Abdallah C,Lejamtel C,Benzoubir N,Battaglia S,Sidahmed-Adrar N,Desterke C,Lemasson M,Rosenberg AR,Samuel D,Bréchot C,Pflieger D,Le Naour F,Bourgeade MF.Hepatitis C virus core protein targets 4E-BP1 expression and phosphorylation and potentiates Myc-induced liver carcinogenesis in transgenic mice.Oncotarget 2017;8:56228-56242[PMID:28915586 DOI:10.18632/oncotarget.17280]
21 Kasprzak A,Adamek A.Role of hepatitis C virus proteins(C,NS3,NS5A)in hepatic oncogenesis.Hepatol Res 2008;38:1-26[PMID:17894800 DOI:10.1111/j.1872-034X.2007.00261.x]
22 Liu J,Ding X,Tang J,Cao Y,Hu P,Zhou F,Shan X,Cai X,Chen Q,Ling N,Zhang B,Bi Y,Chen K,Ren H,Huang A,He TC,Tang N.Enhancement of canonical Wnt/β-catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells.PLoS One 2011;6:e27496[PMID:22110662 DOI:10.1371/journal.pone.0027496]
23 Jiang YF,He B,Li NP,Ma J,Gong GZ,Zhang M.The oncogenic role of NS5A of hepatitis C virus is mediated by up-regulation of survivin gene expression in the hepatocellular cell through p53and NF-κB pathways.Cell Biol Int 2011;35:1225-1232[PMID:21612579 DOI:10.1042/CBI20110102]
24 Qadri I,Iwahashi M,Capasso JM,Hopken MW,Flores S,Schaack J,Simon FR.Induced oxidative stress and activated expression of manganese superoxide dismutase during hepatitis Cvirus replication:role of JNK,p38 MAPK and AP-1.Biochem J 2004;378:919-928[PMID:14670077DOI:10.1042/BJ20031587]
25 Boulant S,Vanbelle C,Ebel C,Penin F,Lavergne JP.Hepatitis C virus core protein is a dimeric alpha-helical protein exhibiting membrane protein features.J Virol 2005;79:11353-11365[PMID:16103187 DOI:10.1128/JVI.79.17.11353-11365.2005]
26 Kunkel M,Watowich SJ.Biophysical characterization of hepatitis C virus core protein:implications for interactions within the virus and host.FEBS Lett 2004;557:174-180[PMID:14741363 DOI:10.1016/S0014-5793(03)01486-8]
27 Bartosch B,Thimme R,Blum HE,Zoulim F.Hepatitis C virus-induced hepatocarcinogenesis.JHepatol 2009;51:810-820[PMID:19545926 DOI:10.1016/j.jhep.2009.05.008]
28 Taniguchi H,Kato N,Otsuka M,Goto T,Yoshida H,Shiratori Y,Omata M.Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription.J Med Virol 2004;72:52-59[PMID:14635011 DOI:10.1002/jmv.10545]
29 Joo M,Hahn YS,Kwon M,Sadikot RT,Blackwell TS,Christman JW.Hepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta.J Virol 2005;79:7648-7657[PMID:15919917 DOI:10.1128/JVI.79.12.7648-7657.2005]
30 Jahan S,Khaliq S,Ijaz B,Ahmad W,Hassan S.Role of HCV Core gene of genotype 1a and 3a and host gene Cox-2 in HCV-induced pathogenesis.Virol J 2011;8:155[PMID:21457561 DOI:10.1186/1743-422X-8-155]
31 Hassan M,Selimovic D,Ghozlan H,Abdel-kader O.Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways.Hepatology 2009;49:1469-1482[PMID:19235829 DOI:10.1002/hep.22849]
32 Dharancy S,Malapel M,Perlemuter G,Roskams T,Cheng Y,Dubuquoy L,Podevin P,Conti F,Canva V,Philippe D,Gambiez L,Mathurin P,Paris JC,Schoonjans K,Calmus Y,Pol S,Auwerx J,Desreumaux P.Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection.Gastroenterology 2005;128:334-342[PMID:15685545 DOI:10.1053/j.gastro.2004.11.016]
33 MassaguéJ.TGFbeta in Cancer.Cell 2008;134:215-230[PMID:18662538 DOI:10.1016/j.cell.2008.07.001]
34 Syed V.TGF-βSignaling in Cancer.J Cell Biochem 2016;117:1279-1287[PMID:26774024 DOI:10.1002/jcb.25496]
35 Xu F,Liu C,Zhou D,Zhang L.TGF-β/SMAD Pathway and Its Regulation in Hepatic Fibrosis.JHistochem Cytochem 2016;64:157-167[PMID:26747705 DOI:10.1369/0022155415627681]
36 Biernacka A,Dobaczewski M,Frangogiannis NG.TGF-βsignaling in fibrosis.Growth Factors2011;29:196-202[PMID:21740331 DOI:10.3109/08977194.2011.595714]
37 Mirzaei H,Faghihloo E.Viruses as key modulators of the TGF-βpathway;a double-edged sword involved in cancer.Rev Med Virol 2018;28[PMID:29345394 DOI:10.1002/rmv.1967]
38 Gordon KJ,Blobe GC.Role of transforming growth factor-beta superfamily signaling pathways in human disease.Biochim Biophys Acta 2008;1782:197-228[PMID:18313409 DOI:10.1016/j.bbadis.2008.01.006]
39 Blobe GC,Schiemann WP,Lodish HF.Role of transforming growth factor beta in human disease.N Engl J Med 2000;342:1350-1358[PMID:10793168 DOI:10.1056/NEJM200005043421807]
40 Derynck R,Zhang YE.Smad-dependent and Smad-independent pathways in TGF-beta family signalling.Nature 2003;425:577-584[PMID:14534577 DOI:10.1038/nature02006]
41 Moustakas A,Heldin CH.The regulation of TGFbeta signal transduction.Development 2009;136:3699-3714[PMID:19855013 DOI:10.1242/dev.030338]
42 Ikushima H,Miyazono K.TGFbeta signalling:a complex web in cancer progression.Nat Rev Cancer 2010;10:415-424[PMID:20495575 DOI:10.1038/nrc2853]
43 Zhang YE.Non-Smad pathways in TGF-beta signaling.Cell Res 2009;19:128-139[PMID:19114990 DOI:10.1038/cr.2008.328]
44 Wu JW,Hu M,Chai J,Seoane J,Huse M,Li C,Rigotti DJ,Kyin S,Muir TW,Fairman R,MassaguéJ,Shi Y.Crystal structure of a phosphorylated Smad2.Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling.Mol Cell 2001;8:1277-1289[PMID:11779503 DOI:10.1016/S1097-2765(01)00421-X]
45 Budi EH,Duan D,Derynck R.Transforming Growth Factor-βReceptors and Smads:Regulatory Complexity and Functional Versatility.Trends Cell Biol 2017;27:658-672[PMID:28552280 DOI:10.1016/j.tcb.2017.04.005]
46 Imamura T,Oshima Y,Hikita A.Regulation of TGF-βfamily signalling by ubiquitination and deubiquitination.J Biochem 2013;154:481-489[PMID:24165200 DOI:10.1093/jb/mvt097]
47 Yu L,Hébert MC,Zhang YE.TGF-beta receptor-activated p38 MAP kinase mediates Smadindependent TGF-beta responses.EMBO J 2002;21:3749-3759[PMID:12110587 DOI:10.1093/emboj/cdf366]
48 Presser LD,McRae S,Waris G.Activation of TGF-β1 promoter by hepatitis C virus-induced AP-1 and Sp1:role of TGF-β1 in hepatic stellate cell activation and invasion.PLoS One 2013;8:e56367[PMID:23437118 DOI:10.1371/journal.pone.0056367]
49 Bedossa P,Poynard T,Mathurin P,Lemaigre G,Chaput JC.Transforming growth factor beta 1:in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon.Gut 1993;34:S146-S147[PMID:8314486 DOI:10.1136/gut.34.2_Suppl.S146]
50 Paradis V,Mathurin P,Laurent A,Charlotte F,Vidaud M,Poynard T,Hoang C,Opolon P,Bedossa P.Histological features predictive of liver fibrosis in chronic hepatitis C infection.J Clin Pathol 1996;49:998-1004[PMID:9038738 DOI:10.1136/jcp.49.12.998]
51 Ray S,Broor SL,Vaishnav Y,Sarkar C,Girish R,Dar L,Seth P,Broor S.Transforming growth factor beta in hepatitis C virus infection:in vivo and in vitro findings.J Gastroenterol Hepatol 2003;18:393-403[PMID:12653887 DOI:10.1046/j.1440-1746.2003.02985.x]
52 Jee MH,Hong KY,Park JH,Lee JS,Kim HS,Lee SH,Jang SK.New Mechanism of Hepatic Fibrogenesis:Hepatitis C Virus Infection Induces Transforming Growth Factorβ1 Production through Glucose-Regulated Protein 94.J Virol 2015;90:3044-3055[PMID:26719248 DOI:10.1128/JVI.02976-15]
53 Benzoubir N,Lejamtel C,Battaglia S,Testoni B,Benassi B,Gondeau C,Perrin-Cocon L,Desterke C,Thiers V,Samuel D,Levrero M,Bréchot C,Bourgeade MF.HCV core-mediated activation of latent TGF-βvia thrombospondin drives the crosstalk between hepatocytes and stromal environment.J Hepatol 2013;59:1160-1168[PMID:23928402 DOI:10.1016/j.jhep.2013.07.036]
54 Shin JY,Hur W,Wang JS,Jang JW,Kim CW,Bae SH,Jang SK,Yang SH,Sung YC,Kwon OJ,Yoon SK.HCV core protein promotes liver fibrogenesis via up-regulation of CTGF with TGF-beta1.Exp Mol Med 2005;37:138-145[PMID:15886528 DOI:10.1038/emm.2005.19]
55 Chusri P,Kumthip K,Hong J,Zhu C,Duan X,Jilg N,Fusco DN,Brisac C,Schaefer EA,Cai D,Peng LF,Maneekarn N,Lin W,Chung RT.HCV induces transforming growth factorβ1 through activation of endoplasmic reticulum stress and the unfolded protein response.Sci Rep 2016;6:22487[PMID:26927933 DOI:10.1038/srep22487]
56 Lin W,Tsai WL,Shao RX,Wu G,Peng LF,Barlow LL,Chung WJ,Zhang L,Zhao H,Jang JY,Chung RT.Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner.Gastroenterology 2010;138:2509-2518,2518.e1[PMID:20230822 DOI:10.1053/j.gastro.2010.03.008]
57 Battaglia S,Benzoubir N,Nobilet S,Charneau P,Samuel D,Zignego AL,Atfi A,Bréchot C,Bourgeade MF.Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition.PLoS One 2009;4:e4355[PMID:19190755 DOI:10.1371/journal.pone.0004355]
58 Pavio N,Battaglia S,Boucreux D,Arnulf B,Sobesky R,Hermine O,Brechot C.Hepatitis C virus core variants isolated from liver tumor but not from adjacent non-tumor tissue interact with Smad3 and inhibit the TGF-beta pathway.Oncogene 2005;24:6119-6132[PMID:16007207 DOI:10.1038/sj.onc.1208749]
59 Macias MJ,Martin-Malpartida P,MassaguéJ.Structural determinants of Smad function in TGF-βsignaling.Trends Biochem Sci 2015;40:296-308[PMID:25935112 DOI:10.1016/j.tibs.2015.03.012]
60 Cheng PL,Chang MH,Chao CH,Lee YH.Hepatitis C viral proteins interact with Smad3 and differentially regulate TGF-beta/Smad3-mediated transcriptional activation.Oncogene 2004;23:7821-7838[PMID:15334054 DOI:10.1038/sj.onc.1208066]
61 Erhardt A,Hassan M,Heintges T,H?ussinger D.Hepatitis C virus core protein induces cell proliferation and activates ERK,JNK,and p38 MAP kinases together with the MAP kinase phosphatase MKP-1 in a HepG2 Tet-Off cell line.Virology 2002;292:272-284[PMID:11878930DOI:10.1006/viro.2001.1227]
62 Okuda M,Li K,Beard MR,Showalter LA,Scholle F,Lemon SM,Weinman SA.Mitochondrial injury,oxidative stress,and antioxidant gene expression are induced by hepatitis C virus core protein.Gastroenterology 2002;122:366-375[PMID:11832451 DOI:10.1053/gast.2002.30983]
63 Kotsiri I,Hadziyannis E,Georgiou A,Papageorgiou MV,Vlachogiannakos I,Papatheodoridis G.Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy.Ann Gastroenterol 2016;29:79-84[PMID:26752952]
64 Tsushima H,Kawata S,Tamura S,Ito N,Shirai Y,Kiso S,Doi Y,Yamada A,Oshikawa O,Matsuzawa Y.Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy:association with regression of hepatic fibrosis.JHepatol 1999;30:1-7[PMID:9927144 DOI:10.1016/S0168-8278(99)80001-4]
65 Flisiak R,Jaroszewicz J,Lapinski TW,Flisiak I,Prokopowiczi D.Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-beta1,metalloproteinase-1,and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C.World J Gastroenterol 2005;11:6833-6838[PMID:16425392 DOI:10.3748/wjg.v11.i43.6833]
66 Janczewska-Kazek E,Marek B,Kajdaniuk D,Borgiel-Marek H.Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-beta1,vascular endothelial growth factor,and basic fibroblast growth factor in patients with chronic hepatitis C.World JGastroenterol 2006;12:961-965[PMID:16521228 DOI:10.3748/wjg.v12.i6.961]
67 Holmes DI,Zachary I.The vascular endothelial growth factor(VEGF)family:angiogenic factors in health and disease.Genome Biol 2005;6:209[PMID:15693956 DOI:10.1186/gb-2005-6-2-209]
68 Koch S,Claesson-Welsh L.Signal transduction by vascular endothelial growth factor receptors.Cold Spring Harb Perspect Med 2012;2:a006502[PMID:22762016 DOI:10.1101/cshperspect.a006502]
69 Ferrara N.Vascular endothelial growth factor as a target for anticancer therapy.Oncologist 2004;9 Suppl 1:2-10[PMID:15178810 DOI:10.1634/theoncologist.9-suppl_1-2]
70 Goel HL,Mercurio AM.VEGF targets the tumour cell.Nat Rev Cancer 2013;13:871-882[PMID:24263190 DOI:10.1038/nrc3627]
71 Carmeliet P.VEGF as a key mediator of angiogenesis in cancer.Oncology 2005;69 Suppl 3:4-10[PMID:16301830 DOI:10.1159/000088478]
72 Lemus-Varela ML,Flores-Soto ME,Cervantes-Munguía R,Torres-Mendoza BM,Gudi?oCabrera G,Chaparro-Huerta V,Ortu?o-Sahagún D,Beas-Zárate C.Expression of HIF-1 alpha,VEGF and EPO in peripheral blood from patients with two cardiac abnormalities associated with hypoxia.Clin Biochem 2010;43:234-239[PMID:19804771 DOI:10.1016/j.clinbiochem.2009.09.022]
73 Wong C,Wellman TL,Lounsbury KM.VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer.Gynecol Oncol 2003;91:513-517[PMID:14675669DOI:10.1016/j.ygyno.2003.08.022]
74 Poon RT,Fan ST,Wong J.Clinical implications of circulating angiogenic factors in cancer patients.J Clin Oncol 2001;19:1207-1225[PMID:11181687 DOI:10.1200/JCO.2001.19.4.1207]
75 Alkharsah KR.VEGF Upregulation in Viral Infections and Its Possible Therapeutic Implications.Int J Mol Sci 2018;19[PMID:29865171 DOI:10.3390/ijms19061642]
76 Llovet JM,Pe?a CE,Lathia CD,Shan M,Meinhardt G,Bruix J;SHARP Investigators Study Group.Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.Clin Cancer Res 2012;18:2290-2300[PMID:22374331 DOI:10.1158/1078-0432.CCR-11-2175]
77 Mukozu T,Nagai H,Matsui D,Kanekawa T,Sumino Y.Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma.Anticancer Res 2013;33:1013-1021[PMID:23482775]
78 Yvamoto EY,Ferreira RF,Nogueira V,Pinhe MA,Tenani GD,Andrade JG,Baitello ME,Gregório ML,Fucuta PS,Silva RF,Souza DR,Silva RC.Influence of vascular endothelial growth factor and alpha-fetoprotein on hepatocellular carcinoma.Genet Mol Res 2015;14:17453-17462[PMID:26782388 DOI:10.4238/2015.December.21.16]
79 Nasimuzzaman M,Waris G,Mikolon D,Stupack DG,Siddiqui A.Hepatitis C virus stabilizes hypoxia-inducible factor 1alpha and stimulates the synthesis of vascular endothelial growth factor.J Virol 2007;81:10249-10257[PMID:17626077 DOI:10.1128/JVI.00763-07]
80 Mee CJ,Farquhar MJ,Harris HJ,Hu K,Ramma W,Ahmed A,Maurel P,Bicknell R,Balfe P,McKeating JA.Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner.Gastroenterology 2010;138:1134-1142[PMID:19944696 DOI:10.1053/j.gastro.2009.11.047]
81 Shimoda K,Mori M,Shibuta K,Banner BF,Barnard GF.Vascular endothelial growth factor/vascular permeability factor mRNA expression in patients with chronic hepatitis C and hepatocellular carcinoma.Int J Oncol 1999;14:353-359[PMID:9917513 DOI:10.3892/ijo.14.2.353]
82 Abe M,Koga H,Yoshida T,Masuda H,Iwamoto H,Sakata M,Hanada S,Nakamura T,Taniguchi E,Kawaguchi T,Yano H,Torimura T,Ueno T,Sata M.Hepatitis C virus core protein upregulates the expression of vascular endothelial growth factor via the nuclear factor-κB/hypoxia-inducible factor-1αaxis under hypoxic conditions.Hepatol Res 2012;42:591-600[PMID:22221855 DOI:10.1111/j.1872-034X.2011.00953.x]
83 Zhu C,Liu X,Wang S,Yan X,Tang Z,Wu K,Li Y,Liu F.Hepatitis C virus core protein induces hypoxia-inducible factor 1α-mediated vascular endothelial growth factor expression in Huh7.5.1cells.Mol Med Rep 2014;9:2010-2014[PMID:24626461 DOI:10.3892/mmr.2014.2039]
84 Liu XH,Zhou X,Zhu CL,Song H,Liu F.[Effects of HCV core protein on the expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor].Zhonghua Gan Zang Bing Za Zhi 2011;19:751-754[PMID:22409847 DOI:10.3760/cma.j.issn.1007-3418.2011.10.008]
85 Shao YY,Hsieh MS,Wang HY,Li YS,Lin H,Hsu HW,Huang CY,Hsu CH,Cheng AL.Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells.Oncotarget 2017;8:86681-86692[PMID:29156827 DOI:10.18632/oncotarget.21407]
86 Tzeng HE,Tsai CH,Chang ZL,Su CM,Wang SW,Hwang WL,Tang CH.Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma.Biochem Pharmacol 2013;85:531-540[PMID:23219526 DOI:10.1016/j.bcp.2012.11.021]
87 Dong W,Li Y,Gao M,Hu M,Li X,Mai S,Guo N,Yuan S,Song L.IKKαcontributes to UVB-induced VEGF expression by regulating AP-1 transactivation.Nucleic Acids Res 2012;40:2940-2955[PMID:22169952 DOI:10.1093/nar/gkr1216]
88 Tsutsumi T,Suzuki T,Moriya K,Yotsuyanagi H,Shintani Y,Fujie H,Matsuura Y,Kimura S,Koike K,Miyamura T.Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein.Virology 2002;304:415-424[PMID:12504580 DOI:10.1006/viro.2002.1702]
89 Shrivastava A,Manna SK,Ray R,Aggarwal BB.Ectopic expression of hepatitis C virus core protein differentially regulates nuclear transcription factors.J Virol 1998;72:9722-9728[PMID:9811706]
90 Kanda T,Steele R,Ray R,Ray RB.Hepatitis C virus core protein augments androgen receptormediated signaling.J Virol 2008;82:11066-11072[PMID:18768969 DOI:10.1128/JVI.01300-08]
91 Komiya Y,Habas R.Wnt signal transduction pathways.Organogenesis 2008;4:68-75[PMID:19279717 DOI:10.4161/org.4.2.5851]
92 Monga SP.β-Catenin Signaling and Roles in Liver Homeostasis,Injury,and Tumorigenesis.Gastroenterology 2015;148:1294-1310[PMID:25747274 DOI:10.1053/j.gastro.2015.02.056]
93 Nelson WJ,Nusse R.Convergence of Wnt,beta-catenin,and cadherin pathways.Science 2004;303:1483-1487[PMID:15001769 DOI:10.1126/science.1094291]
94 Kikuchi A,Yamamoto H,Sato A,Matsumoto S.New insights into the mechanism of Wnt signaling pathway activation.Int Rev Cell Mol Biol 2011;291:21-71[PMID:22017973 DOI:10.1016/B978-0-12-386035-4.00002-1]
95 Clevers H,Nusse R.Wnt/β-catenin signaling and disease.Cell 2012;149:1192-1205[PMID:22682243 DOI:10.1016/j.cell.2012.05.012]
96 MacDonald BT,Tamai K,He X.Wnt/beta-catenin signaling:components,mechanisms,and diseases.Dev Cell 2009;17:9-26[PMID:19619488 DOI:10.1016/j.devcel.2009.06.016]
97 King TD,Zhang W,Suto MJ,Li Y.Frizzled7 as an emerging target for cancer therapy.Cell Signal2012;24:846-851[PMID:22182510 DOI:10.1016/j.cellsig.2011.12.009]
98 Logan CY,Nusse R.The Wnt signaling pathway in development and disease.Annu Rev Cell Dev Biol 2004;20:781-810[PMID:15473860 DOI:10.1146/annurev.cellbio.20.010403.113126]
99 Nusse R,Clevers H.Wnt/β-Catenin Signaling,Disease,and Emerging Therapeutic Modalities.Cell 2017;169:985-999[PMID:28575679 DOI:10.1016/j.cell.2017.05.016]
100 Reya T,Clevers H.Wnt signalling in stem cells and cancer.Nature 2005;434:843-850[PMID:15829953 DOI:10.1038/nature03319]
101 Heuberger J,Birchmeier W.Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling.Cold Spring Harb Perspect Biol 2010;2:a002915[PMID:20182623 DOI:10.1101/cshperspect.a002915]
102 Flanagan DJ,Austin CR,Vincan E,Phesse TJ.Wnt Signalling in Gastrointestinal Epithelial Stem Cells.Genes(Basel)2018;9[PMID:29570681 DOI:10.3390/genes9040178]
103 Wallingford JB,Habas R.The developmental biology of Dishevelled:an enigmatic protein governing cell fate and cell polarity.Development 2005;132:4421-4436[PMID:16192308 DOI:10.1242/dev.02068]
104 Klaus A,Birchmeier W.Wnt signalling and its impact on development and cancer.Nat Rev Cancer 2008;8:387-398[PMID:18432252 DOI:10.1038/nrc2389]
105 Jeong WJ,Ro EJ,Choi KY.Interaction between Wnt/β-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations ofβ-catenin and RAS by targeting the Wnt/β-catenin pathway.NPJ Precis Oncol 2018;2:5[PMID:29872723 DOI:10.1038/s41698-018-0049-y]
106 Trischler J,Shiomi T,Turner DL,Sklepkiewicz PL,Goldklang MP,Tanaka KF,Xu M,Farber DL,D'Armiento JM.Immune Modulation of the T Cell Response in Asthma through Wnt10b.Am JRespir Cell Mol Biol 2016;54:584-593[PMID:26436894 DOI:10.1165/rcmb.2014-0425OC]
107 Reuter S,Martin H,Beckert H,Bros M,Montermann E,Belz C,Heinz A,Ohngemach S,Sahin U,Stassen M,Buhl R,Eshkind L,Taube C.The Wnt/β-catenin pathway attenuates experimental allergic airway disease.J Immunol 2014;193:485-495[PMID:24929002 DOI:10.4049/jimmunol.1400013]
108 Wang W,Pan Q,Fuhler GM,Smits R,Peppelenbosch MP.Action and function of Wnt/β-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma.J Gastroenterol2017;52:419-431[PMID:28035485 DOI:10.1007/s00535-016-1299-5]
109 Anson M,Crain-Denoyelle AM,Baud V,Chereau F,Gougelet A,Terris B,Yamagoe S,Colnot S,Viguier M,Perret C,Couty JP.Oncogenicβ-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice.J Clin Invest 2012;122:586-599[PMID:22251704 DOI:10.1172/JCI43937]
110 Zeng G,Awan F,Otruba W,Muller P,Apte U,Tan X,Gandhi C,Demetris AJ,Monga SP.Wnt'er in liver:expression of Wnt and frizzled genes in mouse.Hepatology 2007;45:195-204[PMID:17187422 DOI:10.1002/hep.21473]
111 Wang Q,Chou X,Guan F,Fang Z,Lu S,Lei J,Li Y,Liu W.Enhanced Wnt Signalling in Hepatocytes is Associated with Schistosoma japonicum Infection and Contributes to Liver Fibrosis.Sci Rep 2017;7:230[PMID:28331224 DOI:10.1038/s41598-017-00377-4]
112 Khanizadeh S,Hasanvand B,Esmaeil Lashgarian H,Almasian M,Goudarzi G.Interaction of viral oncogenic proteins with the Wnt signaling pathway.Iran J Basic Med Sci 2018;21:651-659[PMID:30140402 DOI:10.22038/IJBMS.2018.28903.6982]
113 Liu J,Wang Z,Tang J,Tang R,Shan X,Zhang W,Chen Q,Zhou F,Chen K,Huang A,Tang N.Hepatitis C virus core protein activates Wnt/β-catenin signaling through multiple regulation of upstream molecules in the SMMC-7721 cell line.Arch Virol 2011;156:1013-1023[PMID:21340743DOI:10.1007/s00705-011-0943-x]
114 Quan H,Zhou F,Nie D,Chen Q,Cai X,Shan X,Zhou Z,Chen K,Huang A,Li S,Tang N.Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition.Oncogene 2014;33:2826-2835[PMID:23770846DOI:10.1038/onc.2013.225]
115 Umer M,Qureshi SA,Hashmi ZY,Raza A,Ahmad J,Rahman M,Iqbal M.Promoter hypermethylation of Wnt pathway inhibitors in hepatitis C virus-induced multistep hepatocarcinogenesis.Virol J 2014;11:117[PMID:24947038 DOI:10.1186/1743-422X-11-117]
116 Ripoli M,Barbano R,Balsamo T,Piccoli C,Brunetti V,Coco M,Mazzoccoli G,Vinciguerra M,Pazienza V.Hypermethylated levels of E-cadherin promoter in Huh-7 cells expressing the HCVcore protein.Virus Res 2011;160:74-81[PMID:21640770 DOI:10.1016/j.virusres.2011.05.014]
117 Jhaveri R,Kundu P,Shapiro AM,Venkatesan A,Dasgupta A.Effect of heptitis C virus core protein on cellular gene expression:specific inhibition of cyclooxygenase 2.J Infect Dis 2005;191:1498-1506[PMID:15809909 DOI:10.1086/429301]
118 Simmons DL,Botting RM,Hla T.Cyclooxygenase isozymes:the biology of prostaglandin synthesis and inhibition.Pharmacol Rev 2004;56:387-437[PMID:15317910 DOI:10.1124/pr.56.3.3]
119 Chen WC,Tseng CK,Chen YH,Lin CK,Hsu SH,Wang SN,Lee JC.HCV NS5A Up-Regulates COX-2 Expression via IL-8-Mediated Activation of the ERK/JNK MAPK Pathway.PLoS One2015;10:e0133264[PMID:26231035 DOI:10.1371/journal.pone.0133264]
120 Greenhough A,Smartt HJ,Moore AE,Roberts HR,Williams AC,Paraskeva C,Kaidi A.The COX-2/PGE2 pathway:key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.Carcinogenesis 2009;30:377-386[PMID:19136477 DOI:10.1093/carcin/bgp014]
121 Nú?ez O,Fernández-Martínez A,Majano PL,Apolinario A,Gómez-Gonzalo M,Benedicto I,López-Cabrera M,BoscáL,Clemente G,García-Monzón C,Martín-Sanz P.Increased intrahepatic cyclooxygenase 2,matrix metalloproteinase 2,and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection:role of viral core and NS5A proteins.Gut 2004;53:1665-1672[PMID:15479690 DOI:10.1136/gut.2003.038364]
122 Cheng AS,Chan HL,Leung WK,To KF,Go MY,Chan JY,Liew CT,Sung JJ.Expression of HBx and COX-2 in chronic hepatitis B,cirrhosis and hepatocellular carcinoma:implication of HBx in upregulation of COX-2.Mod Pathol 2004;17:1169-1179[PMID:15218507 DOI:10.1038/modpathol.3800196]
123 Kaul R,Verma SC,Murakami M,Lan K,Choudhuri T,Robertson ES.Epstein-Barr virus protein can upregulate cyclo-oxygenase-2 expression through association with the suppressor of metastasis Nm23-H1.J Virol 2006;80:1321-1331[PMID:16415009 DOI:10.1128/JVI.80.3.1321-1331.2006]
124 Subbaramaiah K,Dannenberg AJ.Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins:evidence of a corepressor/coactivator exchange.Cancer Res 2007;67:3976-3985[PMID:17440114 DOI:10.1158/0008-5472.CAN-06-4273]
125 Moss SF,Blaser MJ.Mechanisms of disease:Inflammation and the origins of cancer.Nat Clin Pract Oncol 2005;2:90-7;quiz 1 p following 113[PMID:16264881 DOI:10.1038/ncponc0081]
126 Aggarwal BB,Vijayalekshmi RV,Sung B.Targeting inflammatory pathways for prevention and therapy of cancer:short-term friend,long-term foe.Clin Cancer Res 2009;15:425-430[PMID:19147746 DOI:10.1158/1078-0432.CCR-08-0149]
127 Gomaa WM,Ibrahim MA,Shatat ME.Overexpression of cyclooxygenase-2 and transforming growth factor-beta 1 is an independent predictor of poor virological response to interferon therapy in chronic HCV genotype 4 patients.Saudi J Gastroenterol 2014;20:59-65[PMID:24496160 DOI:10.4103/1319-3767.126324]
128 Trujillo-Murillo K,Alvarez-Martínez O,Garza-Rodríguez L,Martínez-Rodríguez H,BosquesPadilla F,Ramos-Jiménez J,Barrera-Salda?a H,Rincón-Sánchez AR,Rivas-Estilla AM.Additive effect of ethanol and HCV subgenomic replicon expression on COX-2 protein levels and activity.J Viral Hepat 2007;14:608-617[PMID:17697012 DOI:10.1111/j.1365-2893.2006.00837.x]
129 Trujillo-Murillo K,Rincón-Sánchez AR,Martínez-Rodríguez H,Bosques-Padilla F,RamosJiménez J,Barrera-Salda?a HA,Rojkind M,Rivas-Estilla AM.Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways.Hepatology 2008;47:1462-1472[PMID:18393288 DOI:10.1002/hep.22215]
130 Ivanov AV,Bartosch B,Smirnova OA,Isaguliants MG,Kochetkov SN.HCV and oxidative stress in the liver.Viruses 2013;5:439-469[PMID:23358390 DOI:10.3390/v5020439]
131 Waris G,Siddiqui A.Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress:role of prostaglandin E2 in RNA replication.J Virol 2005;79:9725-9734[PMID:16014934 DOI:10.1128/JVI.79.15.9725-9734.2005]
132 Simula MP,De Re V.Hepatitis C virus-induced oxidative stress and mitochondrial dysfunction:a focus on recent advances in proteomics.Proteomics Clin Appl 2010;4:782-793[PMID:21137022DOI:10.1002/prca.201000049]
133 Jahan S,Ashfaq UA,Qasim M,Khaliq S,Saleem MJ,Afzal N.Hepatitis C virus to hepatocellular carcinoma.Infect Agent Cancer 2012;7:2[PMID:22289144 DOI:10.1186/1750-9378-7-2]
134 Madejón A,Sheldon J,Francisco-Recuero I,Perales C,Domínguez-Beato M,Lasa M,SánchezPerez I,MuntanéJ,Domingo E,García-Samaniego J,Sánchez-Pacheco A.Hepatitis C virusmediated Aurora B kinase inhibition modulates inflammatory pathway and viral infectivity.JHepatol 2015;63:312-319[PMID:25733156 DOI:10.1016/j.jhep.2015.02.036]
135 Friedman SL.Liver fibrosis--from bench to bedside.J Hepatol 2003;38 Suppl 1:S38-S53[PMID:12591185 DOI:10.1016/S0168-8278(02)00429-4]
136 Callejas NA,Casado M,Díaz-Guerra MJ,BoscáL,Martín-Sanz P.Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and-9 in fetal rat hepatocytes.Hepatology2001;33:860-867[PMID:11283850 DOI:10.1053/jhep.2001.23002]
137 Ivanov AV,Smirnova OA,Petrushanko IY,Ivanova ON,Karpenko IL,Alekseeva E,Sominskaya I,Makarov AA,Bartosch B,Kochetkov SN,Isaguliants MG.HCV core protein uses multiple mechanisms to induce oxidative stress in human hepatoma Huh7 cells.Viruses 2015;7:2745-2770[PMID:26035647 DOI:10.3390/v7062745]
138 Lan T,Kisseleva T,Brenner DA.Deficiency of NOX1 or NOX4 Prevents Liver Inflammation and Fibrosis in Mice through Inhibition of Hepatic Stellate Cell Activation.PLoS One 2015;10:e0129743[PMID:26222337 DOI:10.1371/journal.pone.0129743]
139 Castellone MD,Teramoto H,Williams BO,Druey KM,Gutkind JS.Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis.Science 2005;310:1504-1510[PMID:16293724 DOI:10.1126/science.1116221]
140 Yamanaka Y,Shiraki K,Inoue T,Miyashita K,Fuke H,Yamaguchi Y,Yamamoto N,Ito K,Sugimoto K,Nakano T.COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.Int J Mol Med 2006;18:41-47[PMID:16786154 DOI:10.3892/ijmm.18.1.41]
141 Leng J,Han C,Demetris AJ,Michalopoulos GK,Wu T.Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation:evidence for Akt inhibition in celecoxib-induced apoptosis.Hepatology 2003;38:756-768[PMID:12939602 DOI:10.1053/jhep.2003.50380]
142 Ye Y,Xu Y,Lai Y,He W,Li Y,Wang R,Luo X,Chen R,Chen T.Long non-coding RNA cox-2prevents immune evasion and metastasis of hepatocellular carcinoma by altering M1/M2macrophage polarization.J Cell Biochem 2018;119:2951-2963[PMID:29131381 DOI:10.1002/jcb.26509]
143 Tyagi S,Gupta P,Saini AS,Kaushal C,Sharma S.The peroxisome proliferator-activated receptor:A family of nuclear receptors role in various diseases.J Adv Pharm Technol Res 2011;2:236-240[PMID:22247890 DOI:10.4103/2231-4040.90879]
144 Michalik L,Wahli W.PPARs Mediate Lipid Signaling in Inflammation and Cancer.PPAR Res2008;2008:134059[PMID:19125181 DOI:10.1155/2008/134059]
145 Ament Z,Masoodi M,Griffin JL.Applications of metabolomics for understanding the action of peroxisome proliferator-activated receptors(PPARs)in diabetes,obesity and cancer.Genome Med2012;4:32[PMID:22546357 DOI:10.1186/gm331]
146 Agriesti F,Tataranni T,Ruggieri V,Capitanio N,Piccoli C.PPARs and HCV-Related Hepatocarcinoma:A Mitochondrial Point of View.PPAR Res 2012;2012:605302[PMID:22966221DOI:10.1155/2012/605302]
147 Ashby J,Brady A,Elcombe CR,Elliott BM,Ishmael J,Odum J,Tugwood JD,Kettle S,Purchase IF.Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis.Hum Exp Toxicol 1994;13 Suppl 2:S1-117[PMID:7857698 DOI:10.1177/096032719401300201]
148 Saha SA,Kizhakepunnur LG,Bahekar A,Arora RR.The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials.Am Heart J 2007;154:943-953[PMID:17967602 DOI:10.1016/j.ahj.2007.07.011]
149 Issemann I,Green S.Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators.Nature 1990;347:645-650[PMID:2129546 DOI:10.1038/347645a0]
150 Peters JM,Cattley RC,Gonzalez FJ.Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643.Carcinogenesis 1997;18:2029-2033[PMID:9395198 DOI:10.1093/carcin/18.11.2029]
151 Tanaka N,Moriya K,Kiyosawa K,Koike K,Aoyama T.Hepatitis C virus core protein induces spontaneous and persistent activation of peroxisome proliferator-activated receptor alpha in transgenic mice:implications for HCV-associated hepatocarcinogenesis.Int J Cancer 2008;122:124-131[PMID:17764115 DOI:10.1002/ijc.23056]
152 Yan F,Wang Q,Xu C,Cao M,Zhou X,Wang T,Yu C,Jing F,Chen W,Gao L,Zhao J.Peroxisome proliferator-activated receptorαactivation induces hepatic steatosis,suggesting an adverse effect.PLoS One 2014;9:e99245[PMID:24926685 DOI:10.1371/journal.pone.0099245]
153 Ohata K,Hamasaki K,Toriyama K,Matsumoto K,Saeki A,Yanagi K,Abiru S,Nakagawa Y,Shigeno M,Miyazoe S,Ichikawa T,Ishikawa H,Nakao K,Eguchi K.Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection.Cancer2003;97:3036-3043[PMID:12784339 DOI:10.1002/cncr.11427]
154 Koike K.Steatosis,liver injury,and hepatocarcinogenesis in hepatitis C viral infection.JGastroenterol 2009;44 Suppl 19:82-88[PMID:19148799 DOI:10.1007/s00535-008-2276-4]
155 Tanaka N,Moriya K,Kiyosawa K,Koike K,Gonzalez FJ,Aoyama T.PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice.JClin Invest 2008;118:683-694[PMID:18188449 DOI:10.1172/JCI33594]
156 Shen W,Gao Y,Lu B,Zhang Q,Hu Y,Chen Y.Negatively regulating TLR4/NF-κB signaling via PPARαin endotoxin-induced uveitis.Biochim Biophys Acta 2014;1842:1109-1120[PMID:24717912 DOI:10.1016/j.bbadis.2014.03.015]
157 Barger PM,Browning AC,Garner AN,Kelly DP.p38 mitogen-activated protein kinase activates peroxisome proliferator-activated receptor alpha:a potential role in the cardiac metabolic stress response.J Biol Chem 2001;276:44495-44501[PMID:11577087 DOI:10.1074/jbc.M105945200]
158 Tsutsumi T,Suzuki T,Shimoike T,Suzuki R,Moriya K,Shintani Y,Fujie H,Matsuura Y,Koike K,Miyamura T.Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity.Hepatology 2002;35:937-946[PMID:11915042 DOI:10.1053/jhep.2002.32470]
2 White MK,Pagano JS,Khalili K.Viruses and human cancers:a long road of discovery of molecular paradigms.Clin Microbiol Rev 2014;27:463-481[PMID:24982317 DOI:10.1128/CMR.00124-13]
3 Dubuisson J,Cosset FL.Virology and cell biology of the hepatitis C virus life cycle:an update.JHepatol 2014;61:S3-S13[PMID:25443344 DOI:10.1016/j.jhep.2014.06.031]
4 Taherkhani R,Farshadpour F.Global elimination of hepatitis C virus infection:Progresses and the remaining challenges.World J Hepatol 2017;9:1239-1252[PMID:29312527 DOI:10.4254/wjh.v9.i33.1239]
5 Taherkhani R,Farshadpour F.Lurking epidemic of hepatitis C virus infection in Iran:A call to action.World J Hepatol 2017;9:1040-1042[PMID:28932350 DOI:10.4254/wjh.v9.i24.1040]
6 Maheshwari A,Ray S,Thuluvath PJ.Acute hepatitis C.Lancet 2008;372:321-332[PMID:18657711 DOI:10.1016/S0140-6736(08)61116-2]
7 Taherkhani R,Farshadpour F.Epidemiology of hepatitis C virus in Iran.World J Gastroenterol2015;21:10790-10810[PMID:26478671 DOI:10.3748/wjg.v21.i38.10790]
8 GLOBOCAN 2012 v1.0.Cancer Incidence and Mortality Worldwide:IARC CancerBase No.11.Accessed July 25;2016;Available from:http://www.globocan.iarc.fr/
9 Webster DP,Klenerman P,Dusheiko GM.Hepatitis C.Lancet 2015;385:1124-1135[PMID:25687730 DOI:10.1016/S0140-6736(14)62401-6]
10 Smith-Palmer J,Cerri K,Valentine W.Achieving sustained virologic response in hepatitis C:a systematic review of the clinical,economic and quality of life benefits.BMC Infect Dis 2015;15:19[PMID:25596623 DOI:10.1186/s12879-015-0748-8]
11 Guarino M,Sessa A,Cossiga V,Morando F,Caporaso N,Morisco F;Special Interest Group on“Hepatocellular carcinoma and new anti-HCV therapies”of the Italian Association for the Study of the Liver.Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C:A few lights and many shadows.World J Gastroenterol 2018;24:2582-2595[PMID:29962815 DOI:10.3748/wjg.v24.i24.2582]
12 Aleman S,Rahbin N,Weiland O,Davidsdottir L,Hedenstierna M,Rose N,Verbaan H,St?l P,Carlsson T,Norrgren H,Ekbom A,Granath F,Hultcrantz R.A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis.Clin Infect Dis 2013;57:230-236[PMID:23616492 DOI:10.1093/cid/cit234]
13 El-Serag HB,Kanwal F,Richardson P,Kramer J.Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.Hepatology 2016;64:130-137[PMID:26946190 DOI:10.1002/hep.28535]
14 van der Meer AJ,Feld JJ,Hofer H,Almasio PL,Calvaruso V,Fernández-Rodríguez CM,Aleman S,Ganne-CarriéN,D'Ambrosio R,Pol S,Trapero-Marugan M,Maan R,Moreno-Otero R,Mallet V,Hultcrantz R,Weiland O,Rutter K,Di Marco V,Alonso S,Bruno S,Colombo M,de Knegt RJ,Veldt BJ,Hansen BE,Janssen HLA.Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.J Hepatol 2017;66:485-493[PMID:27780714 DOI:10.1016/j.jhep.2016.10.017]
15 WHO.Hepatitis C,WHO fact sheet.Available from:http://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c
16 Smith DB,Bukh J,Kuiken C,Muerhoff AS,Rice CM,Stapleton JT,Simmonds P.Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes:updated criteria and genotype assignment web resource.Hepatology 2014;59:318-327[PMID:24115039 DOI:10.1002/hep.26744]
17 Pirakitikulr N,Kohlway A,Lindenbach BD,Pyle AM.The Coding Region of the HCV Genome Contains a Network of Regulatory RNA Structures.Mol Cell 2016;62:111-120[PMID:26924328DOI:10.1016/j.molcel.2016.01.024]
18 Tellinghuisen TL,Rice CM.Interaction between hepatitis C virus proteins and host cell factors.Curr Opin Microbiol 2002;5:419-427[PMID:12160863 DOI:10.1016/S1369-5274(02)00341-7]
19 Banerjee A,Ray RB,Ray R.Oncogenic potential of hepatitis C virus proteins.Viruses 2010;2:2108-2133[PMID:21994721 DOI:10.3390/v2092108]
20 Abdallah C,Lejamtel C,Benzoubir N,Battaglia S,Sidahmed-Adrar N,Desterke C,Lemasson M,Rosenberg AR,Samuel D,Bréchot C,Pflieger D,Le Naour F,Bourgeade MF.Hepatitis C virus core protein targets 4E-BP1 expression and phosphorylation and potentiates Myc-induced liver carcinogenesis in transgenic mice.Oncotarget 2017;8:56228-56242[PMID:28915586 DOI:10.18632/oncotarget.17280]
21 Kasprzak A,Adamek A.Role of hepatitis C virus proteins(C,NS3,NS5A)in hepatic oncogenesis.Hepatol Res 2008;38:1-26[PMID:17894800 DOI:10.1111/j.1872-034X.2007.00261.x]
22 Liu J,Ding X,Tang J,Cao Y,Hu P,Zhou F,Shan X,Cai X,Chen Q,Ling N,Zhang B,Bi Y,Chen K,Ren H,Huang A,He TC,Tang N.Enhancement of canonical Wnt/β-catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells.PLoS One 2011;6:e27496[PMID:22110662 DOI:10.1371/journal.pone.0027496]
23 Jiang YF,He B,Li NP,Ma J,Gong GZ,Zhang M.The oncogenic role of NS5A of hepatitis C virus is mediated by up-regulation of survivin gene expression in the hepatocellular cell through p53and NF-κB pathways.Cell Biol Int 2011;35:1225-1232[PMID:21612579 DOI:10.1042/CBI20110102]
24 Qadri I,Iwahashi M,Capasso JM,Hopken MW,Flores S,Schaack J,Simon FR.Induced oxidative stress and activated expression of manganese superoxide dismutase during hepatitis Cvirus replication:role of JNK,p38 MAPK and AP-1.Biochem J 2004;378:919-928[PMID:14670077DOI:10.1042/BJ20031587]
25 Boulant S,Vanbelle C,Ebel C,Penin F,Lavergne JP.Hepatitis C virus core protein is a dimeric alpha-helical protein exhibiting membrane protein features.J Virol 2005;79:11353-11365[PMID:16103187 DOI:10.1128/JVI.79.17.11353-11365.2005]
26 Kunkel M,Watowich SJ.Biophysical characterization of hepatitis C virus core protein:implications for interactions within the virus and host.FEBS Lett 2004;557:174-180[PMID:14741363 DOI:10.1016/S0014-5793(03)01486-8]
27 Bartosch B,Thimme R,Blum HE,Zoulim F.Hepatitis C virus-induced hepatocarcinogenesis.JHepatol 2009;51:810-820[PMID:19545926 DOI:10.1016/j.jhep.2009.05.008]
28 Taniguchi H,Kato N,Otsuka M,Goto T,Yoshida H,Shiratori Y,Omata M.Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription.J Med Virol 2004;72:52-59[PMID:14635011 DOI:10.1002/jmv.10545]
29 Joo M,Hahn YS,Kwon M,Sadikot RT,Blackwell TS,Christman JW.Hepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta.J Virol 2005;79:7648-7657[PMID:15919917 DOI:10.1128/JVI.79.12.7648-7657.2005]
30 Jahan S,Khaliq S,Ijaz B,Ahmad W,Hassan S.Role of HCV Core gene of genotype 1a and 3a and host gene Cox-2 in HCV-induced pathogenesis.Virol J 2011;8:155[PMID:21457561 DOI:10.1186/1743-422X-8-155]
31 Hassan M,Selimovic D,Ghozlan H,Abdel-kader O.Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways.Hepatology 2009;49:1469-1482[PMID:19235829 DOI:10.1002/hep.22849]
32 Dharancy S,Malapel M,Perlemuter G,Roskams T,Cheng Y,Dubuquoy L,Podevin P,Conti F,Canva V,Philippe D,Gambiez L,Mathurin P,Paris JC,Schoonjans K,Calmus Y,Pol S,Auwerx J,Desreumaux P.Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection.Gastroenterology 2005;128:334-342[PMID:15685545 DOI:10.1053/j.gastro.2004.11.016]
33 MassaguéJ.TGFbeta in Cancer.Cell 2008;134:215-230[PMID:18662538 DOI:10.1016/j.cell.2008.07.001]
34 Syed V.TGF-βSignaling in Cancer.J Cell Biochem 2016;117:1279-1287[PMID:26774024 DOI:10.1002/jcb.25496]
35 Xu F,Liu C,Zhou D,Zhang L.TGF-β/SMAD Pathway and Its Regulation in Hepatic Fibrosis.JHistochem Cytochem 2016;64:157-167[PMID:26747705 DOI:10.1369/0022155415627681]
36 Biernacka A,Dobaczewski M,Frangogiannis NG.TGF-βsignaling in fibrosis.Growth Factors2011;29:196-202[PMID:21740331 DOI:10.3109/08977194.2011.595714]
37 Mirzaei H,Faghihloo E.Viruses as key modulators of the TGF-βpathway;a double-edged sword involved in cancer.Rev Med Virol 2018;28[PMID:29345394 DOI:10.1002/rmv.1967]
38 Gordon KJ,Blobe GC.Role of transforming growth factor-beta superfamily signaling pathways in human disease.Biochim Biophys Acta 2008;1782:197-228[PMID:18313409 DOI:10.1016/j.bbadis.2008.01.006]
39 Blobe GC,Schiemann WP,Lodish HF.Role of transforming growth factor beta in human disease.N Engl J Med 2000;342:1350-1358[PMID:10793168 DOI:10.1056/NEJM200005043421807]
40 Derynck R,Zhang YE.Smad-dependent and Smad-independent pathways in TGF-beta family signalling.Nature 2003;425:577-584[PMID:14534577 DOI:10.1038/nature02006]
41 Moustakas A,Heldin CH.The regulation of TGFbeta signal transduction.Development 2009;136:3699-3714[PMID:19855013 DOI:10.1242/dev.030338]
42 Ikushima H,Miyazono K.TGFbeta signalling:a complex web in cancer progression.Nat Rev Cancer 2010;10:415-424[PMID:20495575 DOI:10.1038/nrc2853]
43 Zhang YE.Non-Smad pathways in TGF-beta signaling.Cell Res 2009;19:128-139[PMID:19114990 DOI:10.1038/cr.2008.328]
44 Wu JW,Hu M,Chai J,Seoane J,Huse M,Li C,Rigotti DJ,Kyin S,Muir TW,Fairman R,MassaguéJ,Shi Y.Crystal structure of a phosphorylated Smad2.Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling.Mol Cell 2001;8:1277-1289[PMID:11779503 DOI:10.1016/S1097-2765(01)00421-X]
45 Budi EH,Duan D,Derynck R.Transforming Growth Factor-βReceptors and Smads:Regulatory Complexity and Functional Versatility.Trends Cell Biol 2017;27:658-672[PMID:28552280 DOI:10.1016/j.tcb.2017.04.005]
46 Imamura T,Oshima Y,Hikita A.Regulation of TGF-βfamily signalling by ubiquitination and deubiquitination.J Biochem 2013;154:481-489[PMID:24165200 DOI:10.1093/jb/mvt097]
47 Yu L,Hébert MC,Zhang YE.TGF-beta receptor-activated p38 MAP kinase mediates Smadindependent TGF-beta responses.EMBO J 2002;21:3749-3759[PMID:12110587 DOI:10.1093/emboj/cdf366]
48 Presser LD,McRae S,Waris G.Activation of TGF-β1 promoter by hepatitis C virus-induced AP-1 and Sp1:role of TGF-β1 in hepatic stellate cell activation and invasion.PLoS One 2013;8:e56367[PMID:23437118 DOI:10.1371/journal.pone.0056367]
49 Bedossa P,Poynard T,Mathurin P,Lemaigre G,Chaput JC.Transforming growth factor beta 1:in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon.Gut 1993;34:S146-S147[PMID:8314486 DOI:10.1136/gut.34.2_Suppl.S146]
50 Paradis V,Mathurin P,Laurent A,Charlotte F,Vidaud M,Poynard T,Hoang C,Opolon P,Bedossa P.Histological features predictive of liver fibrosis in chronic hepatitis C infection.J Clin Pathol 1996;49:998-1004[PMID:9038738 DOI:10.1136/jcp.49.12.998]
51 Ray S,Broor SL,Vaishnav Y,Sarkar C,Girish R,Dar L,Seth P,Broor S.Transforming growth factor beta in hepatitis C virus infection:in vivo and in vitro findings.J Gastroenterol Hepatol 2003;18:393-403[PMID:12653887 DOI:10.1046/j.1440-1746.2003.02985.x]
52 Jee MH,Hong KY,Park JH,Lee JS,Kim HS,Lee SH,Jang SK.New Mechanism of Hepatic Fibrogenesis:Hepatitis C Virus Infection Induces Transforming Growth Factorβ1 Production through Glucose-Regulated Protein 94.J Virol 2015;90:3044-3055[PMID:26719248 DOI:10.1128/JVI.02976-15]
53 Benzoubir N,Lejamtel C,Battaglia S,Testoni B,Benassi B,Gondeau C,Perrin-Cocon L,Desterke C,Thiers V,Samuel D,Levrero M,Bréchot C,Bourgeade MF.HCV core-mediated activation of latent TGF-βvia thrombospondin drives the crosstalk between hepatocytes and stromal environment.J Hepatol 2013;59:1160-1168[PMID:23928402 DOI:10.1016/j.jhep.2013.07.036]
54 Shin JY,Hur W,Wang JS,Jang JW,Kim CW,Bae SH,Jang SK,Yang SH,Sung YC,Kwon OJ,Yoon SK.HCV core protein promotes liver fibrogenesis via up-regulation of CTGF with TGF-beta1.Exp Mol Med 2005;37:138-145[PMID:15886528 DOI:10.1038/emm.2005.19]
55 Chusri P,Kumthip K,Hong J,Zhu C,Duan X,Jilg N,Fusco DN,Brisac C,Schaefer EA,Cai D,Peng LF,Maneekarn N,Lin W,Chung RT.HCV induces transforming growth factorβ1 through activation of endoplasmic reticulum stress and the unfolded protein response.Sci Rep 2016;6:22487[PMID:26927933 DOI:10.1038/srep22487]
56 Lin W,Tsai WL,Shao RX,Wu G,Peng LF,Barlow LL,Chung WJ,Zhang L,Zhao H,Jang JY,Chung RT.Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner.Gastroenterology 2010;138:2509-2518,2518.e1[PMID:20230822 DOI:10.1053/j.gastro.2010.03.008]
57 Battaglia S,Benzoubir N,Nobilet S,Charneau P,Samuel D,Zignego AL,Atfi A,Bréchot C,Bourgeade MF.Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition.PLoS One 2009;4:e4355[PMID:19190755 DOI:10.1371/journal.pone.0004355]
58 Pavio N,Battaglia S,Boucreux D,Arnulf B,Sobesky R,Hermine O,Brechot C.Hepatitis C virus core variants isolated from liver tumor but not from adjacent non-tumor tissue interact with Smad3 and inhibit the TGF-beta pathway.Oncogene 2005;24:6119-6132[PMID:16007207 DOI:10.1038/sj.onc.1208749]
59 Macias MJ,Martin-Malpartida P,MassaguéJ.Structural determinants of Smad function in TGF-βsignaling.Trends Biochem Sci 2015;40:296-308[PMID:25935112 DOI:10.1016/j.tibs.2015.03.012]
60 Cheng PL,Chang MH,Chao CH,Lee YH.Hepatitis C viral proteins interact with Smad3 and differentially regulate TGF-beta/Smad3-mediated transcriptional activation.Oncogene 2004;23:7821-7838[PMID:15334054 DOI:10.1038/sj.onc.1208066]
61 Erhardt A,Hassan M,Heintges T,H?ussinger D.Hepatitis C virus core protein induces cell proliferation and activates ERK,JNK,and p38 MAP kinases together with the MAP kinase phosphatase MKP-1 in a HepG2 Tet-Off cell line.Virology 2002;292:272-284[PMID:11878930DOI:10.1006/viro.2001.1227]
62 Okuda M,Li K,Beard MR,Showalter LA,Scholle F,Lemon SM,Weinman SA.Mitochondrial injury,oxidative stress,and antioxidant gene expression are induced by hepatitis C virus core protein.Gastroenterology 2002;122:366-375[PMID:11832451 DOI:10.1053/gast.2002.30983]
63 Kotsiri I,Hadziyannis E,Georgiou A,Papageorgiou MV,Vlachogiannakos I,Papatheodoridis G.Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy.Ann Gastroenterol 2016;29:79-84[PMID:26752952]
64 Tsushima H,Kawata S,Tamura S,Ito N,Shirai Y,Kiso S,Doi Y,Yamada A,Oshikawa O,Matsuzawa Y.Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy:association with regression of hepatic fibrosis.JHepatol 1999;30:1-7[PMID:9927144 DOI:10.1016/S0168-8278(99)80001-4]
65 Flisiak R,Jaroszewicz J,Lapinski TW,Flisiak I,Prokopowiczi D.Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-beta1,metalloproteinase-1,and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C.World J Gastroenterol 2005;11:6833-6838[PMID:16425392 DOI:10.3748/wjg.v11.i43.6833]
66 Janczewska-Kazek E,Marek B,Kajdaniuk D,Borgiel-Marek H.Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-beta1,vascular endothelial growth factor,and basic fibroblast growth factor in patients with chronic hepatitis C.World JGastroenterol 2006;12:961-965[PMID:16521228 DOI:10.3748/wjg.v12.i6.961]
67 Holmes DI,Zachary I.The vascular endothelial growth factor(VEGF)family:angiogenic factors in health and disease.Genome Biol 2005;6:209[PMID:15693956 DOI:10.1186/gb-2005-6-2-209]
68 Koch S,Claesson-Welsh L.Signal transduction by vascular endothelial growth factor receptors.Cold Spring Harb Perspect Med 2012;2:a006502[PMID:22762016 DOI:10.1101/cshperspect.a006502]
69 Ferrara N.Vascular endothelial growth factor as a target for anticancer therapy.Oncologist 2004;9 Suppl 1:2-10[PMID:15178810 DOI:10.1634/theoncologist.9-suppl_1-2]
70 Goel HL,Mercurio AM.VEGF targets the tumour cell.Nat Rev Cancer 2013;13:871-882[PMID:24263190 DOI:10.1038/nrc3627]
71 Carmeliet P.VEGF as a key mediator of angiogenesis in cancer.Oncology 2005;69 Suppl 3:4-10[PMID:16301830 DOI:10.1159/000088478]
72 Lemus-Varela ML,Flores-Soto ME,Cervantes-Munguía R,Torres-Mendoza BM,Gudi?oCabrera G,Chaparro-Huerta V,Ortu?o-Sahagún D,Beas-Zárate C.Expression of HIF-1 alpha,VEGF and EPO in peripheral blood from patients with two cardiac abnormalities associated with hypoxia.Clin Biochem 2010;43:234-239[PMID:19804771 DOI:10.1016/j.clinbiochem.2009.09.022]
73 Wong C,Wellman TL,Lounsbury KM.VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer.Gynecol Oncol 2003;91:513-517[PMID:14675669DOI:10.1016/j.ygyno.2003.08.022]
74 Poon RT,Fan ST,Wong J.Clinical implications of circulating angiogenic factors in cancer patients.J Clin Oncol 2001;19:1207-1225[PMID:11181687 DOI:10.1200/JCO.2001.19.4.1207]
75 Alkharsah KR.VEGF Upregulation in Viral Infections and Its Possible Therapeutic Implications.Int J Mol Sci 2018;19[PMID:29865171 DOI:10.3390/ijms19061642]
76 Llovet JM,Pe?a CE,Lathia CD,Shan M,Meinhardt G,Bruix J;SHARP Investigators Study Group.Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.Clin Cancer Res 2012;18:2290-2300[PMID:22374331 DOI:10.1158/1078-0432.CCR-11-2175]
77 Mukozu T,Nagai H,Matsui D,Kanekawa T,Sumino Y.Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma.Anticancer Res 2013;33:1013-1021[PMID:23482775]
78 Yvamoto EY,Ferreira RF,Nogueira V,Pinhe MA,Tenani GD,Andrade JG,Baitello ME,Gregório ML,Fucuta PS,Silva RF,Souza DR,Silva RC.Influence of vascular endothelial growth factor and alpha-fetoprotein on hepatocellular carcinoma.Genet Mol Res 2015;14:17453-17462[PMID:26782388 DOI:10.4238/2015.December.21.16]
79 Nasimuzzaman M,Waris G,Mikolon D,Stupack DG,Siddiqui A.Hepatitis C virus stabilizes hypoxia-inducible factor 1alpha and stimulates the synthesis of vascular endothelial growth factor.J Virol 2007;81:10249-10257[PMID:17626077 DOI:10.1128/JVI.00763-07]
80 Mee CJ,Farquhar MJ,Harris HJ,Hu K,Ramma W,Ahmed A,Maurel P,Bicknell R,Balfe P,McKeating JA.Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner.Gastroenterology 2010;138:1134-1142[PMID:19944696 DOI:10.1053/j.gastro.2009.11.047]
81 Shimoda K,Mori M,Shibuta K,Banner BF,Barnard GF.Vascular endothelial growth factor/vascular permeability factor mRNA expression in patients with chronic hepatitis C and hepatocellular carcinoma.Int J Oncol 1999;14:353-359[PMID:9917513 DOI:10.3892/ijo.14.2.353]
82 Abe M,Koga H,Yoshida T,Masuda H,Iwamoto H,Sakata M,Hanada S,Nakamura T,Taniguchi E,Kawaguchi T,Yano H,Torimura T,Ueno T,Sata M.Hepatitis C virus core protein upregulates the expression of vascular endothelial growth factor via the nuclear factor-κB/hypoxia-inducible factor-1αaxis under hypoxic conditions.Hepatol Res 2012;42:591-600[PMID:22221855 DOI:10.1111/j.1872-034X.2011.00953.x]
83 Zhu C,Liu X,Wang S,Yan X,Tang Z,Wu K,Li Y,Liu F.Hepatitis C virus core protein induces hypoxia-inducible factor 1α-mediated vascular endothelial growth factor expression in Huh7.5.1cells.Mol Med Rep 2014;9:2010-2014[PMID:24626461 DOI:10.3892/mmr.2014.2039]
84 Liu XH,Zhou X,Zhu CL,Song H,Liu F.[Effects of HCV core protein on the expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor].Zhonghua Gan Zang Bing Za Zhi 2011;19:751-754[PMID:22409847 DOI:10.3760/cma.j.issn.1007-3418.2011.10.008]
85 Shao YY,Hsieh MS,Wang HY,Li YS,Lin H,Hsu HW,Huang CY,Hsu CH,Cheng AL.Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells.Oncotarget 2017;8:86681-86692[PMID:29156827 DOI:10.18632/oncotarget.21407]
86 Tzeng HE,Tsai CH,Chang ZL,Su CM,Wang SW,Hwang WL,Tang CH.Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma.Biochem Pharmacol 2013;85:531-540[PMID:23219526 DOI:10.1016/j.bcp.2012.11.021]
87 Dong W,Li Y,Gao M,Hu M,Li X,Mai S,Guo N,Yuan S,Song L.IKKαcontributes to UVB-induced VEGF expression by regulating AP-1 transactivation.Nucleic Acids Res 2012;40:2940-2955[PMID:22169952 DOI:10.1093/nar/gkr1216]
88 Tsutsumi T,Suzuki T,Moriya K,Yotsuyanagi H,Shintani Y,Fujie H,Matsuura Y,Kimura S,Koike K,Miyamura T.Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein.Virology 2002;304:415-424[PMID:12504580 DOI:10.1006/viro.2002.1702]
89 Shrivastava A,Manna SK,Ray R,Aggarwal BB.Ectopic expression of hepatitis C virus core protein differentially regulates nuclear transcription factors.J Virol 1998;72:9722-9728[PMID:9811706]
90 Kanda T,Steele R,Ray R,Ray RB.Hepatitis C virus core protein augments androgen receptormediated signaling.J Virol 2008;82:11066-11072[PMID:18768969 DOI:10.1128/JVI.01300-08]
91 Komiya Y,Habas R.Wnt signal transduction pathways.Organogenesis 2008;4:68-75[PMID:19279717 DOI:10.4161/org.4.2.5851]
92 Monga SP.β-Catenin Signaling and Roles in Liver Homeostasis,Injury,and Tumorigenesis.Gastroenterology 2015;148:1294-1310[PMID:25747274 DOI:10.1053/j.gastro.2015.02.056]
93 Nelson WJ,Nusse R.Convergence of Wnt,beta-catenin,and cadherin pathways.Science 2004;303:1483-1487[PMID:15001769 DOI:10.1126/science.1094291]
94 Kikuchi A,Yamamoto H,Sato A,Matsumoto S.New insights into the mechanism of Wnt signaling pathway activation.Int Rev Cell Mol Biol 2011;291:21-71[PMID:22017973 DOI:10.1016/B978-0-12-386035-4.00002-1]
95 Clevers H,Nusse R.Wnt/β-catenin signaling and disease.Cell 2012;149:1192-1205[PMID:22682243 DOI:10.1016/j.cell.2012.05.012]
96 MacDonald BT,Tamai K,He X.Wnt/beta-catenin signaling:components,mechanisms,and diseases.Dev Cell 2009;17:9-26[PMID:19619488 DOI:10.1016/j.devcel.2009.06.016]
97 King TD,Zhang W,Suto MJ,Li Y.Frizzled7 as an emerging target for cancer therapy.Cell Signal2012;24:846-851[PMID:22182510 DOI:10.1016/j.cellsig.2011.12.009]
98 Logan CY,Nusse R.The Wnt signaling pathway in development and disease.Annu Rev Cell Dev Biol 2004;20:781-810[PMID:15473860 DOI:10.1146/annurev.cellbio.20.010403.113126]
99 Nusse R,Clevers H.Wnt/β-Catenin Signaling,Disease,and Emerging Therapeutic Modalities.Cell 2017;169:985-999[PMID:28575679 DOI:10.1016/j.cell.2017.05.016]
100 Reya T,Clevers H.Wnt signalling in stem cells and cancer.Nature 2005;434:843-850[PMID:15829953 DOI:10.1038/nature03319]
101 Heuberger J,Birchmeier W.Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling.Cold Spring Harb Perspect Biol 2010;2:a002915[PMID:20182623 DOI:10.1101/cshperspect.a002915]
102 Flanagan DJ,Austin CR,Vincan E,Phesse TJ.Wnt Signalling in Gastrointestinal Epithelial Stem Cells.Genes(Basel)2018;9[PMID:29570681 DOI:10.3390/genes9040178]
103 Wallingford JB,Habas R.The developmental biology of Dishevelled:an enigmatic protein governing cell fate and cell polarity.Development 2005;132:4421-4436[PMID:16192308 DOI:10.1242/dev.02068]
104 Klaus A,Birchmeier W.Wnt signalling and its impact on development and cancer.Nat Rev Cancer 2008;8:387-398[PMID:18432252 DOI:10.1038/nrc2389]
105 Jeong WJ,Ro EJ,Choi KY.Interaction between Wnt/β-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations ofβ-catenin and RAS by targeting the Wnt/β-catenin pathway.NPJ Precis Oncol 2018;2:5[PMID:29872723 DOI:10.1038/s41698-018-0049-y]
106 Trischler J,Shiomi T,Turner DL,Sklepkiewicz PL,Goldklang MP,Tanaka KF,Xu M,Farber DL,D'Armiento JM.Immune Modulation of the T Cell Response in Asthma through Wnt10b.Am JRespir Cell Mol Biol 2016;54:584-593[PMID:26436894 DOI:10.1165/rcmb.2014-0425OC]
107 Reuter S,Martin H,Beckert H,Bros M,Montermann E,Belz C,Heinz A,Ohngemach S,Sahin U,Stassen M,Buhl R,Eshkind L,Taube C.The Wnt/β-catenin pathway attenuates experimental allergic airway disease.J Immunol 2014;193:485-495[PMID:24929002 DOI:10.4049/jimmunol.1400013]
108 Wang W,Pan Q,Fuhler GM,Smits R,Peppelenbosch MP.Action and function of Wnt/β-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma.J Gastroenterol2017;52:419-431[PMID:28035485 DOI:10.1007/s00535-016-1299-5]
109 Anson M,Crain-Denoyelle AM,Baud V,Chereau F,Gougelet A,Terris B,Yamagoe S,Colnot S,Viguier M,Perret C,Couty JP.Oncogenicβ-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice.J Clin Invest 2012;122:586-599[PMID:22251704 DOI:10.1172/JCI43937]
110 Zeng G,Awan F,Otruba W,Muller P,Apte U,Tan X,Gandhi C,Demetris AJ,Monga SP.Wnt'er in liver:expression of Wnt and frizzled genes in mouse.Hepatology 2007;45:195-204[PMID:17187422 DOI:10.1002/hep.21473]
111 Wang Q,Chou X,Guan F,Fang Z,Lu S,Lei J,Li Y,Liu W.Enhanced Wnt Signalling in Hepatocytes is Associated with Schistosoma japonicum Infection and Contributes to Liver Fibrosis.Sci Rep 2017;7:230[PMID:28331224 DOI:10.1038/s41598-017-00377-4]
112 Khanizadeh S,Hasanvand B,Esmaeil Lashgarian H,Almasian M,Goudarzi G.Interaction of viral oncogenic proteins with the Wnt signaling pathway.Iran J Basic Med Sci 2018;21:651-659[PMID:30140402 DOI:10.22038/IJBMS.2018.28903.6982]
113 Liu J,Wang Z,Tang J,Tang R,Shan X,Zhang W,Chen Q,Zhou F,Chen K,Huang A,Tang N.Hepatitis C virus core protein activates Wnt/β-catenin signaling through multiple regulation of upstream molecules in the SMMC-7721 cell line.Arch Virol 2011;156:1013-1023[PMID:21340743DOI:10.1007/s00705-011-0943-x]
114 Quan H,Zhou F,Nie D,Chen Q,Cai X,Shan X,Zhou Z,Chen K,Huang A,Li S,Tang N.Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition.Oncogene 2014;33:2826-2835[PMID:23770846DOI:10.1038/onc.2013.225]
115 Umer M,Qureshi SA,Hashmi ZY,Raza A,Ahmad J,Rahman M,Iqbal M.Promoter hypermethylation of Wnt pathway inhibitors in hepatitis C virus-induced multistep hepatocarcinogenesis.Virol J 2014;11:117[PMID:24947038 DOI:10.1186/1743-422X-11-117]
116 Ripoli M,Barbano R,Balsamo T,Piccoli C,Brunetti V,Coco M,Mazzoccoli G,Vinciguerra M,Pazienza V.Hypermethylated levels of E-cadherin promoter in Huh-7 cells expressing the HCVcore protein.Virus Res 2011;160:74-81[PMID:21640770 DOI:10.1016/j.virusres.2011.05.014]
117 Jhaveri R,Kundu P,Shapiro AM,Venkatesan A,Dasgupta A.Effect of heptitis C virus core protein on cellular gene expression:specific inhibition of cyclooxygenase 2.J Infect Dis 2005;191:1498-1506[PMID:15809909 DOI:10.1086/429301]
118 Simmons DL,Botting RM,Hla T.Cyclooxygenase isozymes:the biology of prostaglandin synthesis and inhibition.Pharmacol Rev 2004;56:387-437[PMID:15317910 DOI:10.1124/pr.56.3.3]
119 Chen WC,Tseng CK,Chen YH,Lin CK,Hsu SH,Wang SN,Lee JC.HCV NS5A Up-Regulates COX-2 Expression via IL-8-Mediated Activation of the ERK/JNK MAPK Pathway.PLoS One2015;10:e0133264[PMID:26231035 DOI:10.1371/journal.pone.0133264]
120 Greenhough A,Smartt HJ,Moore AE,Roberts HR,Williams AC,Paraskeva C,Kaidi A.The COX-2/PGE2 pathway:key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.Carcinogenesis 2009;30:377-386[PMID:19136477 DOI:10.1093/carcin/bgp014]
121 Nú?ez O,Fernández-Martínez A,Majano PL,Apolinario A,Gómez-Gonzalo M,Benedicto I,López-Cabrera M,BoscáL,Clemente G,García-Monzón C,Martín-Sanz P.Increased intrahepatic cyclooxygenase 2,matrix metalloproteinase 2,and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection:role of viral core and NS5A proteins.Gut 2004;53:1665-1672[PMID:15479690 DOI:10.1136/gut.2003.038364]
122 Cheng AS,Chan HL,Leung WK,To KF,Go MY,Chan JY,Liew CT,Sung JJ.Expression of HBx and COX-2 in chronic hepatitis B,cirrhosis and hepatocellular carcinoma:implication of HBx in upregulation of COX-2.Mod Pathol 2004;17:1169-1179[PMID:15218507 DOI:10.1038/modpathol.3800196]
123 Kaul R,Verma SC,Murakami M,Lan K,Choudhuri T,Robertson ES.Epstein-Barr virus protein can upregulate cyclo-oxygenase-2 expression through association with the suppressor of metastasis Nm23-H1.J Virol 2006;80:1321-1331[PMID:16415009 DOI:10.1128/JVI.80.3.1321-1331.2006]
124 Subbaramaiah K,Dannenberg AJ.Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins:evidence of a corepressor/coactivator exchange.Cancer Res 2007;67:3976-3985[PMID:17440114 DOI:10.1158/0008-5472.CAN-06-4273]
125 Moss SF,Blaser MJ.Mechanisms of disease:Inflammation and the origins of cancer.Nat Clin Pract Oncol 2005;2:90-7;quiz 1 p following 113[PMID:16264881 DOI:10.1038/ncponc0081]
126 Aggarwal BB,Vijayalekshmi RV,Sung B.Targeting inflammatory pathways for prevention and therapy of cancer:short-term friend,long-term foe.Clin Cancer Res 2009;15:425-430[PMID:19147746 DOI:10.1158/1078-0432.CCR-08-0149]
127 Gomaa WM,Ibrahim MA,Shatat ME.Overexpression of cyclooxygenase-2 and transforming growth factor-beta 1 is an independent predictor of poor virological response to interferon therapy in chronic HCV genotype 4 patients.Saudi J Gastroenterol 2014;20:59-65[PMID:24496160 DOI:10.4103/1319-3767.126324]
128 Trujillo-Murillo K,Alvarez-Martínez O,Garza-Rodríguez L,Martínez-Rodríguez H,BosquesPadilla F,Ramos-Jiménez J,Barrera-Salda?a H,Rincón-Sánchez AR,Rivas-Estilla AM.Additive effect of ethanol and HCV subgenomic replicon expression on COX-2 protein levels and activity.J Viral Hepat 2007;14:608-617[PMID:17697012 DOI:10.1111/j.1365-2893.2006.00837.x]
129 Trujillo-Murillo K,Rincón-Sánchez AR,Martínez-Rodríguez H,Bosques-Padilla F,RamosJiménez J,Barrera-Salda?a HA,Rojkind M,Rivas-Estilla AM.Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways.Hepatology 2008;47:1462-1472[PMID:18393288 DOI:10.1002/hep.22215]
130 Ivanov AV,Bartosch B,Smirnova OA,Isaguliants MG,Kochetkov SN.HCV and oxidative stress in the liver.Viruses 2013;5:439-469[PMID:23358390 DOI:10.3390/v5020439]
131 Waris G,Siddiqui A.Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress:role of prostaglandin E2 in RNA replication.J Virol 2005;79:9725-9734[PMID:16014934 DOI:10.1128/JVI.79.15.9725-9734.2005]
132 Simula MP,De Re V.Hepatitis C virus-induced oxidative stress and mitochondrial dysfunction:a focus on recent advances in proteomics.Proteomics Clin Appl 2010;4:782-793[PMID:21137022DOI:10.1002/prca.201000049]
133 Jahan S,Ashfaq UA,Qasim M,Khaliq S,Saleem MJ,Afzal N.Hepatitis C virus to hepatocellular carcinoma.Infect Agent Cancer 2012;7:2[PMID:22289144 DOI:10.1186/1750-9378-7-2]
134 Madejón A,Sheldon J,Francisco-Recuero I,Perales C,Domínguez-Beato M,Lasa M,SánchezPerez I,MuntanéJ,Domingo E,García-Samaniego J,Sánchez-Pacheco A.Hepatitis C virusmediated Aurora B kinase inhibition modulates inflammatory pathway and viral infectivity.JHepatol 2015;63:312-319[PMID:25733156 DOI:10.1016/j.jhep.2015.02.036]
135 Friedman SL.Liver fibrosis--from bench to bedside.J Hepatol 2003;38 Suppl 1:S38-S53[PMID:12591185 DOI:10.1016/S0168-8278(02)00429-4]
136 Callejas NA,Casado M,Díaz-Guerra MJ,BoscáL,Martín-Sanz P.Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and-9 in fetal rat hepatocytes.Hepatology2001;33:860-867[PMID:11283850 DOI:10.1053/jhep.2001.23002]
137 Ivanov AV,Smirnova OA,Petrushanko IY,Ivanova ON,Karpenko IL,Alekseeva E,Sominskaya I,Makarov AA,Bartosch B,Kochetkov SN,Isaguliants MG.HCV core protein uses multiple mechanisms to induce oxidative stress in human hepatoma Huh7 cells.Viruses 2015;7:2745-2770[PMID:26035647 DOI:10.3390/v7062745]
138 Lan T,Kisseleva T,Brenner DA.Deficiency of NOX1 or NOX4 Prevents Liver Inflammation and Fibrosis in Mice through Inhibition of Hepatic Stellate Cell Activation.PLoS One 2015;10:e0129743[PMID:26222337 DOI:10.1371/journal.pone.0129743]
139 Castellone MD,Teramoto H,Williams BO,Druey KM,Gutkind JS.Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis.Science 2005;310:1504-1510[PMID:16293724 DOI:10.1126/science.1116221]
140 Yamanaka Y,Shiraki K,Inoue T,Miyashita K,Fuke H,Yamaguchi Y,Yamamoto N,Ito K,Sugimoto K,Nakano T.COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.Int J Mol Med 2006;18:41-47[PMID:16786154 DOI:10.3892/ijmm.18.1.41]
141 Leng J,Han C,Demetris AJ,Michalopoulos GK,Wu T.Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation:evidence for Akt inhibition in celecoxib-induced apoptosis.Hepatology 2003;38:756-768[PMID:12939602 DOI:10.1053/jhep.2003.50380]
142 Ye Y,Xu Y,Lai Y,He W,Li Y,Wang R,Luo X,Chen R,Chen T.Long non-coding RNA cox-2prevents immune evasion and metastasis of hepatocellular carcinoma by altering M1/M2macrophage polarization.J Cell Biochem 2018;119:2951-2963[PMID:29131381 DOI:10.1002/jcb.26509]
143 Tyagi S,Gupta P,Saini AS,Kaushal C,Sharma S.The peroxisome proliferator-activated receptor:A family of nuclear receptors role in various diseases.J Adv Pharm Technol Res 2011;2:236-240[PMID:22247890 DOI:10.4103/2231-4040.90879]
144 Michalik L,Wahli W.PPARs Mediate Lipid Signaling in Inflammation and Cancer.PPAR Res2008;2008:134059[PMID:19125181 DOI:10.1155/2008/134059]
145 Ament Z,Masoodi M,Griffin JL.Applications of metabolomics for understanding the action of peroxisome proliferator-activated receptors(PPARs)in diabetes,obesity and cancer.Genome Med2012;4:32[PMID:22546357 DOI:10.1186/gm331]
146 Agriesti F,Tataranni T,Ruggieri V,Capitanio N,Piccoli C.PPARs and HCV-Related Hepatocarcinoma:A Mitochondrial Point of View.PPAR Res 2012;2012:605302[PMID:22966221DOI:10.1155/2012/605302]
147 Ashby J,Brady A,Elcombe CR,Elliott BM,Ishmael J,Odum J,Tugwood JD,Kettle S,Purchase IF.Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis.Hum Exp Toxicol 1994;13 Suppl 2:S1-117[PMID:7857698 DOI:10.1177/096032719401300201]
148 Saha SA,Kizhakepunnur LG,Bahekar A,Arora RR.The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials.Am Heart J 2007;154:943-953[PMID:17967602 DOI:10.1016/j.ahj.2007.07.011]
149 Issemann I,Green S.Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators.Nature 1990;347:645-650[PMID:2129546 DOI:10.1038/347645a0]
150 Peters JM,Cattley RC,Gonzalez FJ.Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643.Carcinogenesis 1997;18:2029-2033[PMID:9395198 DOI:10.1093/carcin/18.11.2029]
151 Tanaka N,Moriya K,Kiyosawa K,Koike K,Aoyama T.Hepatitis C virus core protein induces spontaneous and persistent activation of peroxisome proliferator-activated receptor alpha in transgenic mice:implications for HCV-associated hepatocarcinogenesis.Int J Cancer 2008;122:124-131[PMID:17764115 DOI:10.1002/ijc.23056]
152 Yan F,Wang Q,Xu C,Cao M,Zhou X,Wang T,Yu C,Jing F,Chen W,Gao L,Zhao J.Peroxisome proliferator-activated receptorαactivation induces hepatic steatosis,suggesting an adverse effect.PLoS One 2014;9:e99245[PMID:24926685 DOI:10.1371/journal.pone.0099245]
153 Ohata K,Hamasaki K,Toriyama K,Matsumoto K,Saeki A,Yanagi K,Abiru S,Nakagawa Y,Shigeno M,Miyazoe S,Ichikawa T,Ishikawa H,Nakao K,Eguchi K.Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection.Cancer2003;97:3036-3043[PMID:12784339 DOI:10.1002/cncr.11427]
154 Koike K.Steatosis,liver injury,and hepatocarcinogenesis in hepatitis C viral infection.JGastroenterol 2009;44 Suppl 19:82-88[PMID:19148799 DOI:10.1007/s00535-008-2276-4]
155 Tanaka N,Moriya K,Kiyosawa K,Koike K,Gonzalez FJ,Aoyama T.PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice.JClin Invest 2008;118:683-694[PMID:18188449 DOI:10.1172/JCI33594]
156 Shen W,Gao Y,Lu B,Zhang Q,Hu Y,Chen Y.Negatively regulating TLR4/NF-κB signaling via PPARαin endotoxin-induced uveitis.Biochim Biophys Acta 2014;1842:1109-1120[PMID:24717912 DOI:10.1016/j.bbadis.2014.03.015]
157 Barger PM,Browning AC,Garner AN,Kelly DP.p38 mitogen-activated protein kinase activates peroxisome proliferator-activated receptor alpha:a potential role in the cardiac metabolic stress response.J Biol Chem 2001;276:44495-44501[PMID:11577087 DOI:10.1074/jbc.M105945200]
158 Tsutsumi T,Suzuki T,Shimoike T,Suzuki R,Moriya K,Shintani Y,Fujie H,Matsuura Y,Koike K,Miyamura T.Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity.Hepatology 2002;35:937-946[PMID:11915042 DOI:10.1053/jhep.2002.32470]